A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment ...

Please provide your email address to receive an email when new articles are posted on . The ARTISTRY-1 and ARTISTRY-2 studies assessed a novel, single-tablet regimen. Both showed high efficacy and no ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

A Q&A With Shauna Applin, ARNP. AJMC: Despite substantial therapeutic advances since the 1980s, the US is not on pace to achieve the goals of the Ending the HIV Epidemic (EHE) public health initiative ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study ...